Magnesium for Brain Fog, the Ashwagandha Withdrawal Myth, and Oral Testosterone Lands in Canada
Welcome to The RECLAIM Report, my weekly newsletter where I break down evidence-based men’s health, performance, hormones, sleep, body composition, and longevity in five minutes or less.
No miracle hacks. No wellness theatre. No influencer lab-coat cosplay. Just practical health strategy for men who want their body to keep up with their ambition.
On deck today:
A magnesium trial claiming a younger brain, and what the data actually supports
Why ashwagandha cannot replace a deprescribing plan, and why one of these medications is genuinely dangerous to stop cold
Canada approves another oral testosterone, and what the capsule does not change
Happy Saturday,
There is a particular kind of health advice that sells well because it skips the hard part. Take the compound, feel the thing. No assessment, no monitoring, no plan, no follow-up, no one asking what else could be causing the symptom in the first place.
All three stories this week are variations on that theme. A supplement with a genuinely interesting signal and a headline number that outruns its own data. A social media trend telling men to swap prescription medications for an adaptogen, where one version of that swap can put you in an emergency room. And a new approval that makes testosterone easier to take without making it easier to manage.
Here’s what caught my attention this week.
1. Magnesium L-threonate, brain fog, and a very large headline number
A randomized, double-blind, placebo-controlled trial published in January 2026 in Frontiers in Nutrition tested magnesium L-threonate in 100 adults aged 18 to 45 who were unhappy with their sleep. Participants took 2 grams per day for six weeks, with cognition assessed by standardized testing and sleep tracked both subjectively and through Oura Rings.
Overall cognition improved significantly against placebo on the NIH Total Cognition Composite, with favourable effects on working and episodic memory and faster reaction time. Resting heart rate dropped and heart rate variability rose. Subjective sleep impairment improved, though objective sleep measurements did not differ meaningfully between groups.
Then there’s the number doing the rounds online, which is that cognitive age improved by roughly 7.5 years. That figure comes from a calculation based on test performance, not from any measurement of brain structure or biological aging. Perform better on a battery of cognitive tests and the derived age score moves. Nothing in the trial demonstrates that anyone’s brain got younger.
The rest of the fine print deserves the same attention. Six weeks is short. The participants were young and healthy, which tells you very little about a 48-year-old with persistent brain fog, and nothing at all about dementia or ADHD. Several of the positive results sat close to the significance threshold, and one cognitive measure, Raven’s Progressive Matrices, showed no benefit whatsoever. The study was funded by the company that makes the compound and that also helped design the trial. That does not make the results false. It makes independent replication the thing I’m waiting for.
The mechanism is real enough to be interesting. Magnesium participates in NMDA receptor regulation and synaptic plasticity, and animal work going back to Slutsky’s 2010 Neuron paper suggests L-threonate can raise brain magnesium concentrations in ways other forms may not. What has not been established is that this translates into superiority over magnesium glycinate or citrate for human cognition, or that oral supplementation increases synaptic density in people.
On the custom compounded magnesium and B-vitamin stacks currently being marketed as neurological support: correcting a documented B12 or folate deficiency is legitimate medicine. Selling a combination product to a nutrient-replete adult on the theory that the ingredients should work well together is not the same thing.
The move this week:
if brain fog is the complaint, magnesium is not the first question. Sleep quality, apnea risk, alcohol, medication burden, iron and B12 status, thyroid, blood pressure, and metabolic health all belong in the assessment first. If you want to trial magnesium L-threonate after that, it is reasonable and low risk. Just buy it as an experiment, not as a brain age reversal.
2. Ashwagandha cannot replace a deprescribing plan
There is a steady stream of content telling men they can get off their anxiety or antidepressant medication with an adaptogen and some discipline. Benzodiazepines and SSRIs get lumped together in these posts constantly, and they should not be, because the withdrawal physiology is different and so is the risk.
Benzodiazepines like lorazepam, clonazepam, and alprazolam enhance signaling at GABA-A receptors. With repeated exposure the central nervous system adapts, and physical dependence can develop in a patient taking the medication exactly as prescribed. Stopping abruptly in someone physically dependent can produce rebound anxiety, severe insomnia, tremor, autonomic instability, perceptual disturbance, and seizures, which in severe cases are life threatening. Worth separating two ideas that get conflated: physical dependence is not the same as addiction.
In June 2025 a multidisciplinary group led by the American Society of Addiction Medicine published a joint clinical practice guideline on benzodiazepine tapering. The core recommendation is to avoid abrupt discontinuation in anyone likely to be physically dependent, with typical initial reductions of 5 to 10 percent every two to four weeks, adjusted according to symptoms and risk. For some patients the taper needs to be considerably slower and can run for months.
SSRIs work through a different mechanism, inhibiting the serotonin transporter and driving longer-term neurophysiological adaptation. Discontinuation symptoms follow the FINISH pattern: flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances including electric shock sensations, and hyperarousal. These are frequently mistaken for relapse of the original condition, which is how men end up convinced they need the medication forever when what they actually needed was a slower taper. Conventional SSRI discontinuation does not carry the same seizure risk as benzodiazepine withdrawal, though symptoms can still be severe and prolonged.
Horowitz and Taylor’s 2019 Lancet Psychiatry paper is why hyperbolic tapering keeps coming up. The relationship between dose and serotonin transporter occupancy is nonlinear, so dropping from 20 mg to 10 mg is pharmacologically different from dropping from 10 mg to zero, despite the identical milligram reduction. Their proposal was progressively smaller reductions as the dose approaches zero. It is a mechanistically informed proposal rather than a large randomized trial, and the Royal College of Psychiatrists has since published practical guidance along similar lines.
This is where compounding earns its place. Commercial dosage forms frequently cannot deliver the small decrements the final stage of a taper requires. Depending on the drug, stability data, and regulatory requirements, we can work with prescribers on lower-strength commercial products, suitable oral liquids, or patient-specific compounded strengths with a coordinated monitoring plan. Not every patient needs this. Many do fine on conventional schedules.
As for ashwagandha, some preparations have small studies suggesting benefit for stress and sleep symptoms. There is no evidence it prevents benzodiazepine withdrawal seizures or treats SSRI discontinuation syndrome. It also carries its own issues, including sedative interactions, effects on thyroid function, and rare reports of liver injury.
The move this week:
if you want off a psychiatric medication, that is a legitimate goal and a conversation worth having. Have it with your prescriber and your pharmacist, with a written taper schedule and a follow-up plan. Never stop a benzodiazepine abruptly on your own. The supplement aisle is not a withdrawal safety net.
3. A new oral testosterone has been approved in Canada
Health Canada has approved TLANDO, an oral testosterone undecanoate product, adding another option to the small group of oral testosterone products available here. It joins JATENZO, which is already listed, so this is a new entrant rather than a first. Lipocine has announced that Canadian partner Verity Pharmaceuticals intends to launch by the end of 2026, which means approval is done and availability is not. Your physician cannot write for it yet.
The formulation is genuinely clever. Older oral androgens were 17-alpha-alkylated compounds with real hepatic toxicity, which is why oral testosterone carried a bad reputation for decades. Testosterone undecanoate is a lipophilic ester absorbed with substantial involvement of intestinal lymphatic transport, which reduces first-pass hepatic exposure. Different drug, different liver risk profile.
What TLANDO adds beyond that is a fixed-dose approach. US prescribing information lists 225 mg twice daily with food, with serum testosterone measured eight to nine hours after the morning dose at three to four weeks to decide whether treatment continues.
What the capsule does not change is that this is systemic testosterone replacement. Oral testosterone undecanoate may elevate blood pressure, can drive erythrocytosis, suppresses LH and FSH with meaningful impact on sperm production, requires prostate assessment and PSA monitoring where clinically appropriate, and carries the same caution around severe untreated sleep apnea as every other route. Describing an oral capsule as a natural testosterone booster would be false. The negative feedback on the hypothalamic-pituitary axis works the same way regardless of how the testosterone gets in.
The diagnostic standard has not moved either. The Endocrine Society asks for symptoms or signs consistent with androgen deficiency, consistently low concentrations confirmed on two separate morning fasting total testosterone measurements, free testosterone where SHBG is altered or results are borderline, and LH and FSH to establish the cause. Roughly 30 percent of men with an initial low result come back normal on retest, because illness, poor sleep, calorie restriction, and metabolic disturbance all move the number.
The move this week:
if an oral option appeals to you because you dislike needles, that is a reasonable preference and worth raising with your physician. Just do not let the delivery format shorten the workup. Two morning fasting draws, a cause investigated, fertility goals discussed before the first dose, and a monitoring plan covering hematocrit, blood pressure, PSA where appropriate, and symptoms. Easier to swallow is not the same as easier to manage.
My favorite thing this week
Michael J. Fox being promoted to Companion of the Order of Canada at Rideau Hall on October 2, alongside 50 other Canadians.
He’s a local kid. He grew up in Burnaby, and for a lot of us out here that detail never fully stops being a point of pride. Back to the Future remains one of my favourite films, and I'm comfortable enough debating its validity as one of the greatest trilogies in movie history.
He was diagnosed with Parkinson’s in 1991 at 29. He went public in 1998 and started his foundation in 2000, and the thing I keep coming back to is what that foundation actually built. Not awareness. Infrastructure.
Parkinson’s involves the progressive loss of dopamine-producing neurons in the substantia nigra, which produces the tremor, rigidity, and slowed movement most people recognize. The parts people miss are the sleep disruption, constipation, loss of smell, depression, and fatigue, some of which can show up years before anything visible happens to movement. Diagnosis has historically been clinical, meaning a neurologist watching a patient move and making a judgment call.
In 2023, researchers working through the foundation’s Parkinson’s Progression Markers Initiative validated an assay that detects misfolded alpha-synuclein in cerebrospinal fluid, reporting 87.7 percent sensitivity and 96.3 percent specificity in that cohort. Performance varied across genetic and clinical subgroups, so it does not replace a neurological assessment. What it offers is the possibility of identifying the underlying biology, sometimes before motor symptoms appear, which changes who can be enrolled in trials of therapies meant to slow progression.
There is still no cure. Levodopa, dopamine agonists, and deep brain stimulation manage symptoms without stopping the underlying degeneration. But the men reading this are mostly in the business of optimizing a body that still works well. Fox spent three decades building the scientific machinery for a disease that was taking his, and was honest in public about the parts of it that are not inspiring. That seems worth a paragraph this weekend.
Client conversation of the week
A client came in frustrated. He lost weight well in the first stretch of his program, and the scale has now been flat for weeks. He is training consistently, his sleep is genuinely good since he started CPAP, he is not cheating his nutrition, and he cannot understand why the number has stopped moving.
Then he mentioned his pants fit differently and his waist measurement has dropped.
That detail changes the entire interpretation. Weight is a single number representing fat, muscle, water, glycogen, and gut contents all stacked together, and it has no obligation to tell you which one changed. A man who is lifting regularly, eating enough protein, and sleeping properly is building muscle at the same time he is losing fat. Those two changes partially cancel on the scale while producing a visibly different body.
Waist circumference is the more informative measurement here, because it tracks the fat that is actually associated with metabolic and cardiovascular risk. His waist is down, his training numbers are up, his sleep is handled, and his body composition is improving. The scale is just reporting the sum and leaving out the interesting part.
We changed what he tracks. Waist measurement every two weeks under the same conditions, strength progression in a few key lifts, how his clothes fit, energy and recovery, and a DEXA scan if he wants an actual number on fat and lean mass instead of inferring it. He can still weigh himself. He just stops treating the result as a verdict.
What I did not do was tell him to cut calories harder, which is where this usually goes wrong. He is training well, sleeping well, recovering well, and shrinking. Aggressively restricting a man in that position is an efficient way to cost him the muscle he is currently building.
One quote to finish your week strong
“The intensity of the conviction that a hypothesis is true has no bearing on whether it is true or not.”
— Peter Medawar
Medawar won a Nobel Prize in medicine and wrote that line in Advice to a Young Scientist, aimed at researchers who had fallen in love with their own theories.
It applies to the supplement aisle and the comment section with almost no adjustment. The men telling you to drop your SSRI and take an adaptogen are not lying. Most of them believe it completely. The magnesium headline about a younger brain is being shared by people who are genuinely excited rather than cynical. Conviction is cheap and it is contagious, and it produces no evidence at all.
Ask what was measured, in whom, for how long, and who paid for it. That question is unglamorous and it survives contact with confident people, which is more than most of your instincts will.
Final thought
The theme this week is judgment over enthusiasm.
Magnesium L-threonate has a real signal and a headline that outran it. Deprescribing is legitimate and often overdue, and attempting it with a supplement instead of a taper plan is how men end up in trouble. Oral testosterone is a genuine advance in delivery and changes nothing about the diagnosis, the fertility conversation, or the monitoring. And a stalled scale frequently means the plan is working in a way the scale cannot see.
Better tools do not remove the requirement to think. That’s why RECLAIM exists. Not to chase the newest compound, but to work out what is actually driving the decline in your energy, sleep, recovery, body composition, and hormones, then build a plan around the full picture.
If your body is no longer matching your ambition, start with clarity.
Book a RECLAIM fit call:
PS. If you are a man in your 30s, 40s, or 50s and your energy, sleep, body composition, or confidence has quietly slipped, RECLAIM was built for that exact conversation. Book the fit call and let’s find the actual bottleneck.
References
Lopresti AL, Smith SJ. Randomized, double-blind, placebo-controlled trial of magnesium L-threonate (Magtein) in adults with sleep dissatisfaction. Frontiers in Nutrition. 2026.
Slutsky I, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010.
American Society of Addiction Medicine. Joint Clinical Practice Guideline on Benzodiazepine Tapering. June 2025.
Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. 2019.
Royal College of Psychiatrists. Stopping Antidepressants. Patient and clinician guidance.
NIH National Center for Complementary and Integrative Health. Ashwagandha: safety and evidence summary.
Health Canada Drug Product Database. TLANDO (testosterone undecanoate), DIN 02572036.
Lipocine Inc. Canadian approval announcement. October 7, 2026.
TLANDO US Prescribing Information.
Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification. The Lancet Neurology. 2023.
Governor General of Canada. Order of Canada investiture ceremony, October 2, 2026.
